Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Gunn, Shelly ^a,b,c   Yeh, I Tien ^b   Lytvak, Irina ^b   Tirtorahardjo, Budi ^a   Dzidic, Natasha ^a   Zadeh, Soheila ^a   Kim, Jaeweon ^a   McCaskill, Chris ^a   Lim, Lony ^a   Gorre, Mercedes ^a   Mohammed, Mansoor ^a  

^a Combimatrix Molecular Diagnostics ^*  (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c START Center for Cancer Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

AMPLICON; ARTICLE; CANCER DIAGNOSIS; CENTROMERE; CHROMOSOMAL INSTABILITY; CHROMOSOME 17; CHROMOSOME ANALYSIS; CHROMOSOME LOSS; CHROMOSOME REARRANGEMENT; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA EXTRACTION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE LOCUS; GENETIC GAIN; HUMAN; HUMAN TISSUE; INSTRUMENT VALIDATION; INTRADUCTAL CARCINOMA; KARYOTYPING; MONOSOMY; BREAST TUMOR; CHROMOSOME ABERRATION; DNA MICROARRAY; FEMALE; GENE DOSAGE; GENETICS; PAGET NIPPLE DISEASE; PATHOLOGY;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE DOSAGE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, ERBB-2;

EID: 77955496491     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-396     Document Type: Article

References (19)

1. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145. 10.1200/JCO.2006.09.2775, 17159189.
2. Tuma RS. Inconsistency of HER2 test raises questions. J Natl Cancer Inst 2007, 99:1064-1065. 10.1093/jnci/djm075, 17623788.
3. Dowsett M, Hanna WM, Kockx M, Penault-Liorca F, Gutjhar T, Habben K, vand Vivjer MJ. Standardization of HER2 testing: results of an international proficiency-testing ring study. Modern Pathol 2007, 20:584-591.
4. Yeh IT, Martin MA, Robetorye RS, Bolla AR, McCaskill C, Shah R, Gorre ME, Mohammed MS, Gunn SR. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Modern Pathol 2009, 22:1169-1175.
5. Marchio C, Lambros MB, Gugliotta P, Di Cantogno LVD, Botta C, Pasini B, Tan DSP, Mackay A, Fenwick K, Tamber N, Bussolati G, Asworth A, Reis-Fiho JS, Sapino A. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 2009, 219:16-24. 10.1002/path.2574, 19670217.
6. Press MF. How is Her2 status established when HER2 and chromosome 17 centromere are both amplified?. Am J Clin Pathol 2006, 126:673-674. 10.1309/GM16C01806EFURX7, 17050063.
7. Troxell ML, Bands CD, Lawce HJ, Galperin IB, Baiyee D, West RB, Olson SB, Cherry AM. Evaluation of HER2 status in carcinomas with amplified chromosome 17 centromere status. Am J Clin Pathol 2006, 709-716. 10.1309/9EYM6VE58F2YCD9F, 17050068.
8. Hagenkord JM, Chang CC. The rewards and challenges of array-based karyotyping for clinical oncology applications. Leukemia 2009, 23:829-833. 10.1038/leu.2009.24, 19436309.
9. Gunn SR. The vanguard has entered the clinical laboratory: array-based karyotyping for prognostic markers in chronic lymphocytic leukemia. J Mol Diagn 2010, 12:1-2.
10. Reinholz MM, Bruzek AK, Visscher DW, Lingle WL, Schroeder MJ, Perez EA, Jenkins RB. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol 2009, 10:267-277. 10.1016/S1470-2045(09)70063-4, 19261255.
11. Krishnamurti U, Hammers JL, Folefac DA, Storto PD. Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma. Mod Pathol 2009, 22:1044-1048. 10.1038/modpathol.2009.61, 19396150.
12. Watters AD, Going JJ, Cooke TG, Barlett JM. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat 2003, 77:109-114. 10.1023/A:1021399923825, 12602909.
13. Gunn SR, Gorre ME, Mohammed MS, McCaskill C, Hibbard MK, Barry TS, Yeh IT. Validation of an array CGH test for HER2 status using tumor-targeted DNA extraction from formalin fixed tissue: comparison with frozen tissue results. Cancer Res 2009, 24:835S.
14. Arriola E, Marchio C, Tan DS, Drury SC, Lambros MB, Natrajan R, Rodriguez-Pinilla SM, Mackay A, Tamber N, Fenwick K, Jones C, Dowsett M, Ashworth A, Reis-Filho JS. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest 2008, 88:491-503. 10.1038/labinvest.2008.19, 18332872.
15. Viale G. Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer. J Pathol 2009, 219:1-2. 10.1002/path.2593, 19670216.
16. Moelans CB, de Weger RA, van Diest PJ. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res Treat 2010, 120:1-7. 10.1007/s10549-009-0539-2, 19760503.
17. Bartlett JM, Muro AF, Dunn JA, McConkey C, Jordan S, Twelves CJ, Cameron DA, Thomas J, Campbell FM, Rea DW, Provenzano E, Caldas C, Pharoah P, Hiller L, Earl H, Poole CJ. Predictive markers of anthracycline benefit: a prospectively planned analysis fo the UK Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol 2010,
18. Habermann JK, Doering J, Hauaniem S, Roblick UJ, Bundgen NK, Nicorici D, Kronenwett U, Rathmsgiriswaran S, Mettu RKR, Kruger S, Bruch HP, Auer G, Guo NL, Ried T. The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome. Int J Cancer 2009, 124:1552-1564. 10.1002/ijc.24017, 2707256, 19101988.
19. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Kochli O, Zaber M, Dietrich H, Mross F, Wilber K, Simon R, Sauter G. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 2004, 64:8534-8540. 10.1158/0008-5472.CAN-04-1945, 15574759.